Hortobagyi G - Search Results

1

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.

Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Hennessy BT, et al. Among authors: hortobagyi g. Ann Oncol. 2005 Aug;16(8):1289-96. doi: 10.1093/annonc/mdi253. Epub 2005 May 12. Ann Oncol. 2005. PMID: 15890665 Free article. Review.

2

Risks and benefits of taxanes in breast and ovarian cancer.

Michaud LB, Valero V, Hortobagyi G. Michaud LB, et al. Among authors: hortobagyi g. Drug Saf. 2000 Nov;23(5):401-28. doi: 10.2165/00002018-200023050-00005. Drug Saf. 2000. PMID: 11085347 Review.

3

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.

Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Esmaeli B, et al. Among authors: hortobagyi g. Ann Oncol. 2002 Feb;13(2):218-21. doi: 10.1093/annonc/mdf036. Ann Oncol. 2002. PMID: 11885997 Free article.

4

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.

Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Chedid S, et al. Among authors: hortobagyi g. Cancer Chemother Pharmacol. 2006 Apr;57(4):540-4. doi: 10.1007/s00280-005-0064-x. Epub 2005 Sep 29. Cancer Chemother Pharmacol. 2006. PMID: 16193332 Clinical Trial.

5

A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.

Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. Assikis V, et al. Among authors: hortobagyi g. Cancer. 2003 Jun 1;97(11):2716-23. doi: 10.1002/cncr.11396. Cancer. 2003. PMID: 12767083 Free article. Clinical Trial.

6

Docetaxel for treatment of solid tumours: a systematic review of clinical data.

Montero A, Fossella F, Hortobagyi G, Valero V. Montero A, et al. Among authors: hortobagyi g. Lancet Oncol. 2005 Apr;6(4):229-39. doi: 10.1016/S1470-2045(05)70094-2. Lancet Oncol. 2005. PMID: 15811618 Review.

7

Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.

Montero A, Booser D, Esparza-Guerra L, Murray J, Rosales M, Hortobagyi G, Valero V. Montero A, et al. Among authors: hortobagyi g. Drugs R D. 2005;6(5):299-305. doi: 10.2165/00126839-200506050-00006. Drugs R D. 2005. PMID: 16128600 Clinical Trial. No abstract available.

8

Phase II study of deoxyspergualin in metastatic breast cancer.

Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Dhingra K, et al. Among authors: hortobagyi g. Invest New Drugs. 1994;12(3):235-41. doi: 10.1007/BF00873965. Invest New Drugs. 1994. PMID: 7896543 Clinical Trial.

9

Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Rahman Z, et al. Among authors: hortobagyi g. Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-77-S17-80. Semin Oncol. 1997. PMID: 9374100 Clinical Trial.

10

Effect of CYP2D6 polymorphisms on breast cancer recurrence.

Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Morrow PK, et al. Among authors: hortobagyi g. Cancer. 2012 Mar 1;118(5):1221-7. doi: 10.1002/cncr.26407. Epub 2011 Aug 5. Cancer. 2012. PMID: 21823108 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,203 results

Search Page